I-Pimobendan 74150-27-9 Metabolism PDE inhibitor
Inkokhelo:T/T, L/C
Umsuka Womkhiqizo:China
Imbobo yokuthutha:Beijing/Shanghai/Hangzhou
I-oda (MOQ):1g
Isikhathi esiholayo:3 izinsuku zokusebenza
Amandla okukhiqiza:1kg/ngenyanga
Isimo sesitoreji:Igcinwe endaweni epholile, eyomile, izinga lokushisa legumbi.
Impahla yephakheji:ibhodlela, ibhodlela
Usayizi wephakheji:1g/ibhodlela, 5/ibhodlela, 10g/ibhodlela, 50g/ibhodlela, 500g/ibhodlela
Ulwazi lokuphepha:UN 2811 6.1/PG 3
Isingeniso
I-Pimobendan, umuthi wezilwane.I-calcium sensitizer kanye ne-inhibitor ekhethiwe ye-phosphodiesterase 3 (PDE3) enemiphumela emihle ye-inotropic ne-vasodilator.
I-Pimobendan isetshenziswa ekulawuleni ukuhluleka kwenhliziyo ezinjeni, okuvame ukubangelwa isifo se-myxomatous mitral valve (esaziwa nangokuthi i-endocardiosis), noma i-dilated cardiomyopathy.Ucwaningo selukhombisile ukuthi njenge-monotherapy, i-pimobendan inyusa isikhathi sokusinda futhi ithuthukisa ikhwalithi yokuphila ezigulini ze-canine ezinokuhluleka kwenhliziyo okuhlanganayo okulandela isifo se-mitral valve uma iqhathaniswa ne-benazepril, i-ACE inhibitor.
Ukucaciswa (USP43)
| Into | Ukucaciswa |
| Ukubukeka | Impushana emhlophe noma ephuzi kancane, i-hygroscopic |
| Mp | Cishe 242℃ |
| Ukuncibilika | Ayincibiliki emanzini, incibilika ngokukhululeka ku-dimethylformamide, incibilika kancane ku-acetone naku-methanil. |
| Ukuhlonza | I-spectrophotometry yokumuncwa kwe-infrared, Comparison pimobendan CRS. |
| Isikhathi sokugcinwa kwenani eliphakeme lesixazululo Sesampuli sihambisana naleso sesixazululo sesitoko Esijwayelekile, njengoba sitholwe ekuhlolweni kwe-Organic Impurities. | |
| Izinsimbi ezinzima | ≤10ppm |
| Imbudumbudu | I-P90 ≤ 25μ m |
| Usayizi wezinhlayiya | 20-80 amamitha |
| Izincibilikisi ezisele | ≤ 500ppm |
| Amanzi | ≤ 1.0% |
| Isivivinyo | 98.0%~102.0% |
| Umlotha one-sulphate | ≤ 0.10% |
| Izinto ezihlobene (HPLC) | |
| ukungcola A | ≤ 0.10% |
| ukungcola B | ≤ 0.10% |
| Noma yikuphi okunye ukungcola | ≤ 0.10% |
| Ukungcola okuphelele | ≤ 0.20% |
